Bad news for Knoll Pharmaceutical Co.'s Meridia anti-obesity drug helped buoy investors' confidence in Interneuron Pharmaceuticals Inc. after an FDA panel voted last week against recommending approval of Meridia.

IPIC (Lexington, Mass.), whose Redux dexfenfluramine remains the only drug approved for obesity, gained $4 on Thursday, and closed Friday at $26.25, up $0.625 for the week